Sep. 11 at 1:42 PM
$VNRX $NEO
VNRX and NEO are very similar in what they do, since both are focused on diagnostics and medical testing, aiming to improve how diseases like cancer and other conditions are detected. They’re both small-cap names with innovative technology and huge potential if their platforms gain wider adoption. Because they sit in fast-growing areas of healthcare and are currently trading at relatively low valuations, any positive catalysts like strong trial results, regulatory approvals, or major partnerships could send them flying. That combination of cutting-edge science, growing demand, and low entry prices is why both have the potential to be very bullish and possibly skyrocket.
